Clinical characteristics of DLBCL patients experiencing early disease progression among lower IPI risk groups

We have previously reported early disease progression within 24 months (POD24) could be a surrogate marker for a substantially increased risk of death (2016 The Japanese Society of Hematology annual meeting). The aim of this study was to clarify clinical characteristics of DLBCL patients experiencing POD24 among lower International Prognostic Index (IPI) risk groups.